


FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-252	Serial No. 10/008,062
LIST OF DOCUMENTS CITED BY APPLICANT		Applicants: David Rizzieri et al.	
 (Use several sheets if necessary)		Filing Date October 19, 2001	Group 1682
12.	Broll et al., <i>Expression of tenascin in tumors of the esophagus, small intestine and colorectum</i> , Gen Diag Pathol, 141:111-119 (1995).		
13.	Bullard et al., <i>In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies</i> , J Neurosurg 64:257-262 (1986).		
14.	Bullard et al., <i>Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs)</i> , Nuklearmedizin-Nuclear Med, 25:210-215 (1986).		
15.	Folkman, J., <i>Anti-angiogenesis: new concept for therapy of solid tumors</i> , Ann. Surg., 175:409-416 (1972).		
16.	Forsberg et al., <i>Skin wounds and severed nerves heal normally in mice lacking tenascin-C</i> , Proc Natl Acad Sci USA, 93:6594-6599 (1996).		
17.	Harris et al., <i>A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group</i> , Blood:1361-1392 (1994).		
18.	Harris et al., <i>Growth factors and angiogenesis in breast cancer</i> , Recent Results in Cancer Research, 127:35-41 (1993).		
19.	He et al., <i>Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein Tenascin</i> , J. Neuroimmunol., 52:127-137 (1994).		
20.	Hettasch et al., <i>Tissue transglutaminase expression in human breast cancer</i> , Lab. Invest., 75:637-645 (1996).		
21.	Huse, M., <i>Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda</i> , Science, 246:1275-1281 (1989).		
22.	Jahkola et al., <i>Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis</i> , Int J Cancer, 69:445-447 (1996).		
23.	Jallo et al., <i>Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis</i> , Neurosurgery, 41:1052-1059 (1997).		
24.	Kawakatsu et al., <i>Human carcinoma cells synthesize and secrete tenascin in vitro</i> , Jpn J Cancer Res. 83:1073-1080 (1992).		
25.	Kojima et al., <i>Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells</i> , J Cell Biol., 121:439-448 (1993).		
26.	Kostianovsky et al., <i>Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions</i> , Ultrastructural Pathol, 21:537-544 (1997).		
27.	Kusagawa et al., <i>Expression and degradation of tenascin-C in human lung cancers</i> , British J Cancer, 77:98-102 (1998).		
28.	Mackie EJ, <i>Molecules in focus: tenascin-C</i> , Int J Biochem Cell Biol, 29:1133-1137 (1997).		
29.	Mackie et al., <i>Regulation of tenascin-C expression in Bone Cells by TGF-β</i> , Bone, 22:301-307 (1998).		
30.	Non-Hodgkin's Lymphoma Pathologic Classification Project, <i>National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas</i> , Cancer, 49:2112-2135 (1982).		
31.	Reist et al., <i>Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent</i> , Clinical Cancer Research., 4:2495-2502 (1998).		
32.	Ribatti et al., <i>Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study</i> , Eur J. Haematology, 56:45-53 (1996).		

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

EXAMINER *Am Harri*

DATE CONSIDERED 6/28/2004

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/008,062
		Filing Date	October 19, 2001
		First Named Inventor	David Rizzieri
		Group Art Unit	1619 1642
		Examiner Name	Unknown A.M. Harris
Sheet 1 of 1	Attorney Docket Number	5405.252	



RECEIVED

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
amb	1	5,624,659		Bigner et al.	4/29/1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					T
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
amb	2	Chilosi, Marco, et al., <i>Constitutive Expression of Tenascin in T-Dependent Zones of Human Lymphoid Tissues</i> , American Journal of Pathology, Vol. 143, No. 5, pp. 1348-1355 (November 1993)			
amb	3	Rizzieri, D. A., et al., <i>Markers of Angiogenesis, Factor VIII and Tenascin, Correlate with Disease Activity in Patients with Non-Hodgkin's Lymphoma</i> , Abstract, Blood, Vol. 94, No. 10, Part 2, Supp. 1, page 4339 (15 November 1999)			
amb	4	Rizzieri, D.A., et al., <i>Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma</i> , Abstract, Blood, Vol. 98, No. 11, Part 2, pp. 247b (16 November 2001)			
amb	5	International Search Report, International Application No. PCT/US01/46104 04/01/2002			

**COPY OF PAPERS
ORIGINALLY FILED**

Examiner Signature	<i>amb</i>	Date Considered	6/28/2004
--------------------	------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.